Report cover image

Unresectable Melanoma Drug Pipeline Analysis Report 2025

Publisher Expert Market Research
Published May 25, 2025
Length 200 Pages
SKU # EMAR20146954

Description

Melanoma refers to a type of skin cancer that is primarily caused by exposure to ultraviolet light (UV). They represent only 1% of all skin cancers. However, cancer-related death as a result of melanoma is a significant cause of concern. If not detected or treated early, melanoma can turn into a metastatic disease. Unresectable melanoma or metastatic melanoma is considered an aggressive form of cancer that can be life-threatening. This indicates the urgent need for clinical research efforts to introduce effective treatment options for patients suffering from unresectable melanoma.

Report Coverage

The Unresectable Melanoma Drug Pipeline Report by Expert Market Research gives comprehensive insights into unresectable melanoma drugs currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for unresectable melanoma. The report includes the analysis of over 100 pipeline drugs and 50+ companies . It will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from unresectable melanoma.

The detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to unresectable melanoma are covered.

Unresectable Melanoma Drug Pipeline Outlook

Historically, melanoma has posed a formidable challenge in the field of oncology, especially in its advanced stages. The introduction of targeted therapies and immune checkpoint inhibitors (ICIs) transformed the treatment landscape for the disease in the past decade. Further, the development of immune checkpoint inhibitors designed to target CTLA-4, PD-1, and PD-L1, among others, substantially enhanced the clinical outcomes for unresectable or advanced melanoma. However, significant challenges still remain such as the management of rare melanoma subtypes or the resistance to current treatments in certain cases.

In February 2024, Amtagvi (lifileucel) developed by Iovance Biotherapeutics Inc., the first cellular therapy for the treatment of unresectable or metastatic melanoma, received regulatory approval from the U.S. Food and Drug Administration. Moreover, the increasing research into identifying new genetic mutations and molecular pathways involved in the progression of unresectable melanoma that can be targeted with novel therapies is poised to lead to the expansion of the drug pipeline in the coming years.

Unresectable Melanoma – Drug Pipeline Therapeutic Assessment

This section of the report covers the analysis of unresectable melanoma drugs based on several segmentations including:

By Phase
  • Late-Stage Products (Phase 3 and Phase 4)
  • Mid-Stage Products (Phase 2)
  • Early-Stage Products (Phase I)
  • Preclinical and Discovery Stage Products
By Drug Class
  • Recombinant fusion proteins
  • Small molecule
  • Monoclonal antibody
  • Peptide
  • Polymer
  • Gene therapy
By Route of Administration
  • Oral
  • Parenteral
  • Others
Unresectable Melanoma – Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis , phase II covers a major share of the total clinical trials for unresectable melanoma. There are around 70 drugs in phase II for unresectable melanoma.

Unresectable Melanoma – Pipeline Assessment Segmentation, By Drug Classes

The drug molecules categories covered under unresectable melanoma pipeline analysis include recombinant fusion proteins, small molecules, monoclonal antibodies, peptides, polymer, and gene therapy. The treatment for unresectable melanoma varies depending on the stage of the disease, the genetic mutations present in the tumor, the previous treatments, and the patient's health. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for unresectable melanoma.

Unresectable Melanoma Clinical Trials Assessment – Competitive Dynamics

The EMR report for the unresectable melanoma drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in unresectable melanoma clinical trials:
  • Bristol-Myers Squibb
  • Pfizer
  • Novartis Pharmaceuticals
  • Hoffmann-La Roche
  • Regeneron Pharmaceuticals
  • Amgen
  • IO Biotech
  • Biocad
  • Iovance Biotherapeutics, Inc.
  • R-Pharm
Unresectable Melanoma – Pipeline Drugs Profile

Major drugs currently in the pipeline are as follows:

Drug: IO102-IO103, Drug: Pembrolizumab

The international, randomized, 2-arm study is designed to assess the safety and efficacy profile of IO102-IO103 in combination with pembrolizumab for the treatment of metastatic (advanced) melanoma or previously untreated unresectable melanoma. The trial, enrolling 400+ participants, is sponsored by IO Biotech and is currently under phase III.

Drug: RPH-075, Drug: Keytruda

The objective of the double-blind, randomized study is to compare the safety, efficacy, and immunogenicity of RPH-075 and Keytruda® in unresectable or metastatic skin melanoma patients. The trial is sponsored by R-Pharm and is currently under phase III.

Drug: RO7247669

Sponsored by Hoffmann-La Roche, this randomized, open-label, multicenter, phase II study aims to evaluate the pharmacokinetics (PK), and pharmacodynamics along with the efficacy and safety profile of two dose levels of the drug RO7247669 in around 80 participants with unresectable or metastatic melanoma.

Biological: Lorigerlimab

This open-label Phase I study, sponsored by MacroGenics, is investigating the pharmacokinetics, pharmacodynamics, safety, tolerability, and preliminary antitumor activity of the biological candidate lorigerlimab in an estimated 162 patients with unresectable or metastatic neoplasms.

Reasons To Buy This Report

The Unresectable Melanoma Drug Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for unresectable melanoma. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within unresectable melanoma pipeline insights.

Key Questions Answered in the Unresectable Melanoma – Pipeline Assessment Report
  • What is the current landscape of unresectable melanoma pipeline drugs?
  • How many companies are developing unresectable melanoma drugs?
  • How many phase III and phase IV drugs are currently present in unresectable melanoma pipeline drugs?
  • Which companies/institutions are leading the unresectable melanoma drug development?
  • What is the efficacy and safety profile of unresectable melanoma pipeline drugs?
  • What are the opportunities and challenges present in the unresectable melanoma drug pipeline landscape?
  • Which company is conducting major trials for unresectable melanoma drugs?
  • What geographies are covered for unresectable melanoma clinical trials?
  • What are emerging trends in unresectable melanoma clinical trials?
Related Reports

Global Cancer Therapeutics Market

Global Intraocular Melanoma Treatment Market

Global Cancer Supportive Care Drugs Market

Table of Contents

200 Pages
1 Preface
1.1 Introduction
1.2 Objectives of the Study
1.3 Research Methodology & Assumptions
2 Executive Summary
3 Overview of Unresectable Melanoma
3.1 Signs and Symptoms
3.2 Causes
3.3 Risk Factors
3.4 Diagnosis
3.5 Treatment
4 Patient Profile: Unresectable Melanoma
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Unresectable Melanoma: Epidemiology Snapshot
5.1 Unresectable Melanoma Incidence by Key Markets
5.2 Unresectable Melanoma – Patients Seeking Treatment in Key Markets
6 Unresectable Melanoma: Market Dynamics
6.1 Market Drivers and Constraints
6.2 SWOT Analysis
7 Unresectable Melanoma: Key Facts Covered
7.1 Top Countries Contributing to Clinical Trials in Asia-Pacific
7.2 Top Countries Contributing to Clinical Trials in Europe
7.3 Top Countries Contributing to Clinical Trials in North America
7.4 Top Countries Contributing to Clinical Trials in Other Regions
8 Unresectable Melanoma, Drug Pipeline Assessment
8.1 Assessment by Treatment Type
8.2 Assessment by Route of Administration
8.3 Assessment by Drug Class
9 EMR Drug Pipeline Comparative Analysis
9.1 List of Unresectable Melanoma Pipeline Drugs
9.1.1 By Company
9.1.2 By Phase
9.1.3 By Indication
9.1.4 By Trial Status
9.1.5 By Funder Type
9.2 EMR Attribute Scoring Analysis of Pipeline Drugs (Top Drugs)
10 Unresectable Melanoma Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
10.1 Comparative Analysis for Late-Stage Drugs
10.1.1 Study Type
10.1.2 Recruitment Status
10.1.3 Company
10.1.4 Funder Type
10.2 Product Level Analysis*
10.2.1 Drug: IO102-IO103, Drug: Pembrolizumab
10.2.1.1 Product Description
10.2.1.2 Trial ID
10.2.1.3 Sponsor Name
10.2.1.4 Study Type
10.2.1.5 Drug Class
10.2.1.6 Eligibility Criteria
10.2.1.7 Study Record Dates
10.2.1.7.1 First Submitted
10.2.1.7.2 First Posted
10.2.1.7.3 Last Update Posted
10.2.1.7.4 Last Verified
10.2.1.8 Indication
10.2.1.9 Study Design
10.2.1.10 Recruitment Status
10.2.1.11 Enrollment (Estimated)
10.2.1.12 Location Countries
10.2.1.13 Recent Results
10.2.2 Biological: BCD-217, Biological: BCD-100
10.2.3 Other Drugs
11 Unresectable Melanoma Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
11.1 Comparative Analysis for Mid-Stage Drugs
11.1.1 Study Type
11.1.2 Recruitment Status
11.1.3 Company
11.1.4 Funder Type
11.2 Product Level Analysis*
11.2.1 Drug: RO7247669
11.2.1.1 Product Description
11.2.1.2 Trial ID
11.2.1.3 Sponsor Name
11.2.1.4 Study Type
11.2.1.5 Drug Class
11.2.1.6 Eligibility Criteria
11.2.1.7 Study Record Dates
11.2.1.7.1 First Submitted
11.2.1.7.2 First Posted
11.2.1.7.3 Last Update Posted
11.2.1.7.4 Last Verified
11.2.1.8 Indication
11.2.1.9 Study Design
11.2.1.10 Recruitment Status
11.2.1.11 Enrollment (Estimated)
11.2.1.12 Location Countries
11.2.1.13 Recent Results
11.2.2 Drug: ST-1898 tablets
11.2.3 Other Drugs
12 Unresectable Melanoma Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
12.1 Comparative Analysis for Early-Stage Drugs
12.1.1 Study Type
12.1.2 Recruitment Status
12.1.3 Company
12.1.4 Funder Type
12.2 Product Level Analysis*
12.2.1 Drug: Ceritinib, Drug: Trametinib
12.2.1.1 Product Description
12.2.1.2 Trial ID
12.2.1.3 Sponsor Name
12.2.1.4 Study Type
12.2.1.5 Drug Class
12.2.1.6 Eligibility Criteria
12.2.1.7 Study Record Dates
12.2.1.7.1 First Submitted
12.2.1.7.2 First Posted
12.2.1.7.3 Last Update Posted
12.2.1.7.4 Last Verified
12.2.1.8 Indication
12.2.1.9 Study Design
12.2.1.10 Recruitment Status
12.2.1.11 Enrollment (Estimated)
12.2.1.12 Location Countries
12.2.2 Biological: Lorigerlimab
12.2.3 Other Drugs
13 Unresectable Melanoma Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
13.1 Comparative Analysis for Preclinical and Discovery Stage Drugs
13.1.1 Study Type
13.1.2 Recruitment Status
13.1.3 Company
13.1.4 Funder Type
13.2 Product Level Analysis*
13.2.1 Drug 1
13.2.1.1 Product Description
13.2.1.2 Trial ID
13.2.1.3 Sponsor Name
13.2.1.4 Study Type
13.2.1.5 Drug Class
13.2.1.6 Eligibility Criteria
13.2.1.7 Study Record Dates
13.2.1.7.1 First Submitted
13.2.1.7.2 First Posted
13.2.1.7.3 Last Update Posted
13.2.1.7.4 Last Verified
13.2.1.8 Indication
13.2.1.9 Study Design
13.2.1.10 Recruitment Status
13.2.1.11 Enrollment (Estimated)
13.2.1.12 Location Countries
13.3 Other Drugs
14 Unresectable Melanoma, Key Drug Pipeline Companies
14.1 Bristol-Myers Squibb
14.1.1 Company Snapshot
14.1.2 Pipeline Product Portfolio
14.1.3 Financial Analysis
14.1.4 Recent News and Developments
14.2 Pfizer
14.2.1 Company Snapshot
14.2.2 Pipeline Product Portfolio
14.2.3 Financial Analysis
14.2.4 Recent News and Developments
14.3 Novartis Pharmaceuticals
14.3.1 Company Snapshot
14.3.2 Pipeline Product Portfolio
14.3.3 Financial Analysis
14.3.4 Recent News and Developments
14.4 Hoffmann-La Roche
14.4.1 Company Snapshot
14.4.2 Pipeline Product Portfolio
14.4.3 Financial Analysis
14.4.4 Recent News and Developments
14.5 Regeneron Pharmaceuticals
14.5.1 Company Snapshot
14.5.2 Pipeline Product Portfolio
14.5.3 Financial Analysis
14.5.4 Recent News and Developments
14.6 Amgen
14.6.1 Company Snapshot
14.6.2 Pipeline Product Portfolio
14.6.3 Financial Analysis
14.6.4 Recent News and Developments
14.7 IO Biotech
14.7.1 Company Snapshot
14.7.2 Pipeline Product Portfolio
14.7.3 Financial Analysis
14.7.4 Recent News and Developments
14.8 Biocad
14.8.1 Company Snapshot
14.8.2 Pipeline Product Portfolio
14.8.3 Financial Analysis
14.8.4 Recent News and Developments
14.9 Iovance Biotherapeutics, Inc.
14.9.1 Company Snapshot
14.9.2 Pipeline Product Portfolio
14.9.3 Financial Analysis
14.9.4 Recent News and Developments
14.10 R-Pharm
14.10.1 Company Snapshot
14.10.2 Pipeline Product Portfolio
14.10.3 Financial Analysis
14.10.4 Recent News and Developments
15 Regulatory Framework for Drug Approval, By Region
16 Terminated or Suspended Pipeline Products

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us